Epilepsy and hormones: A critical review

Epilepsy and Behavior

Volumn 15, Issue 1, 2009, Pages 73-77

  Luef, Gerhard ^a   Rauchenzauner, Markus ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Bone; Epilepsy; Hormones; Lipids; Steroid hormones

Indexed keywords

ADIPONECTIN; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; CARBAMAZEPINE; GROWTH HORMONE; LEPTIN; LIPID; NATRIURETIC PEPTIDE TYPE C; OSTEOCALCIN; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; SEX HORMONE; THYROID HORMONE; VALPROIC ACID;

BONE DEVELOPMENT; BONE METABOLISM; BONE TURNOVER; CARDIOLOGY; ENDOCRINOLOGY; EPILEPSY; FRACTURE; HEALTH STATUS; HUMAN; HYPERANDROGENISM; HYPERINSULINEMIA; HYPERLEPTINEMIA; KETOGENIC DIET; LIPID METABOLISM; MEDICAL SPECIALIST; MENOPAUSE; NEUROLOGY; PUBERTY; REVIEW; RISK ASSESSMENT; SIDE EFFECT; SUDDEN DEATH; TESTOSTERONE BLOOD LEVEL; THYROID FUNCTION; THYROID HORMONE BLOOD LEVEL; TREATMENT DURATION; WEIGHT GAIN; WELLBEING;

ANIMALS; BODY WEIGHT; BONE AND BONES; EPILEPSY; HORMONES; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; LIPID METABOLISM; NEUROSECRETORY SYSTEMS; SEX FACTORS;

EID: 67349222551     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2009.02.022     Document Type: Review

References (93)

1. Bauer J., Blumenthal S., Reuber M., and Stoffel-Wagner B. Epilepsy syndrome, focus location, and treatment choice affect testicular function in men with epilepsy. Neurology 62 (2004) 243-246
2. Bilo L., Meo R., Nappi C., et al. Reproductive endocrine disorders in women with primary generalized epilepsy. Epilepsia 29 (1988) 612-619
3. Bilo L., Meo R., Valentino R., Di Carlo C., Striano S., and Nappi C. Characterization of reproductive endocrine disorders in women with epilepsy. J Clin Endocrinol Metab 86 (2001) 2950-2956
4. Cummings L.N., Giudice L., and Morrell M.J. Ovulatory function in epilepsy. Epilepsia 36 (1995) 355-359
5. Herzog A.G., and Fowler K.M. Sensitivity and specificity of the association between catamenial seizure patterns and ovulation. Neurology 70 (2008) 486-487
6. Herzog A.G., Seibel M.M., Schomer D., Vaitukaitis J., and Geschwind N. Temporal lobe epilepsy: an extrahypothalamic pathogenesis for polycystic ovarian syndrome?. Neurology 34 (1984) 1389-1393
7. Herzog A.G., Seibel M.M., Schomer D.L., Vaitukaitis J.L., and Geschwind N. Reproductive endocrine disorders in women with partial seizures of temporal lobe origin. Arch Neurol 43 (1986) 341-346
8. Isojarvi J.I., Laatikainen T.J., Knip M., Pakarinen A.J., Juntunen K.T., and Myllyla V.V. Obesity and endocrine disorders in women taking valproate for epilepsy. Ann Neurol 39 (1996) 579-584
9. Isojarvi J.I., Laatikainen T.J., Pakarinen A.J., Juntunen K.T., and Myllyla V.V. Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. N Engl J Med 329 (1993) 1383-1388
10. Luef G., Abraham I., Trinka E., et al. Hyperandrogenism, postprandial hyperinsulinism and the risk of PCOS in a cross sectional study of women with epilepsy treated with valproate. Epilepsy Res 48 (2002) 91-102
11. Pack A. Bone health in people with epilepsy: is it impaired and what are the risk factors?. Seizure 17 (2008) 181-186
12. Rauchenzauner M., Haberlandt E., Foerster S., et al. Brain-type natriuretic peptide secretion following febrile and afebrile seizures: a new marker in childhood epilepsy?. Epilepsia 48 (2007) 101-106
13. Rauchenzauner M., Klepper J., Leiendecker B., Luef G., Rostasy K., and Ebenbichler C. The ketogenic diet in children with Glut1 deficiency syndrome and epilepsy. J Pediatr 153 (2008) 716-718
14. Sheth R.D., Binkley N., and Hermann B.P. Progressive bone deficit in epilepsy. Neurology 70 (2008) 170-176
15. Verrotti A., Manco R., Scardapane A., and Chiarelli F. Adolescents and epilepsy: hormonal aspects. Minerva Pediatr 60 (2008) 417-428
16. Luef G., and Rauchenzauner M. Epilepsies in girls and women. In: Panayatopoulos C.P. (Ed). The educational kit on epilepsies (2008), Medicinae Press, Oxford 73-82
17. Bauer J. Interactions between hormones and epilepsy in female patients. Epilepsia 42 Suppl. 3 (2001) 20-22
18. De Vries L., Karasik A., Landau Z., Phillip M., Kiviti S., and Goldberg-Stern H. Endocrine effects of valproate in adolescent girls with epilepsy. Epilepsia 48 (2007) 470-477
19. Isojarvi J.I., Pakarinen A.J., Rautio A., Pelkonen O., and Myllyla V.V. Serum sex hormone levels after replacing carbamazepine with oxcarbazepine. Eur J Clin Pharmacol 47 (1995) 461-4644
20. Kim J.Y., and Lee H.W. Metabolic and hormonal disturbances in women with epilepsy on antiepileptic drug monotherapy. Epilepsia 48 (2007) 1366-1370
21. Morrell M.J. Reproductive and metabolic disorders in women with epilepsy. Epilepsia 44 Suppl. 4 (2003) 11-20
22. Vainionpaa L.K., Rattya J., Knip M., et al. Valproate-induced hyperandrogenism during pubertal maturation in girls with epilepsy. Ann Neurol 45 (1999) 444-450
23. Webber M.P., Hauser W.A., Ottman R., and Annegers J.F. Fertility in persons with epilepsy: 1935-974. Epilepsia 27 (1986) 746-752
24. Dana-Haeri J., and Trimble M.R. Prolactin and gonadotrophin changes following partial seizures in epileptic patients with and without psychopathology. Biol Psychiatry 19 (1984) 329-336
25. Herzog A.G. A relationship between particular reproductive endocrine disorders and the laterality of epileptiform discharges in women with epilepsy. Neurology 43 (1993) 1907-1910
26. Herzog A.G., Coleman A.E., Jacobs A.R., et al. Relationship of sexual dysfunction to epilepsy laterality and reproductive hormone levels in women. Epilepsy Behav 4 (2003) 407-413
27. Isojarvi J.I., Tauboll E., and Herzog A.G. Effect of antiepileptic drugs on reproductive endocrine function in individuals with epilepsy. CNS Drugs 19 (2005) 207-223
28. Herzog A.G., Drislane F.W., Schomer D.L., et al. Differential effects of antiepileptic drugs on sexual function and reproductive hormones in men with epilepsy: interim analysis of a comparison between lamotrigine and enzyme-inducing antiepileptic drugs. Epilepsia 45 (2004) 764-768
29. Isojarvi J.I., Laatikainen T.J., Pakarinen A.J., Juntunen K.T., and Myllyla V.V. Menstrual disorders in women with epilepsy receiving carbamazepine. Epilepsia 36 (1995) 676-681
30. Isojarvi J.I., Pakarinen A.J., Ylipalosaari P.J., and Myllyla V.V. Serum hormones in male epileptic patients receiving anticonvulsant medication. Arch Neurol 47 (1990) 670-676
31. Isojarvi J.I., Repo M., Pakarinen A.J., Lukkarinen O., and Myllyla V.V. Carbamazepine, phenytoin, sex hormones, and sexual function in men with epilepsy. Epilepsia 36 (1995) 366-370
32. Lofgren E., Tapanainen J.S., Koivunen R., Pakarinen A., and Isojarvi J.I. Effects of carbamazepine and oxcarbazepine on the reproductive endocrine function in women with epilepsy. Epilepsia 47 (2006) 1441-1446
33. Luef G., Abraham I., Haslinger M., et al. Polycystic ovaries, obesity and insulin resistance in women with epilepsy: a comparative study of carbamazepine and valproic acid in 105 women. J Neurol 249 (2002) 835-841
34. Bauer J., Isojarvi J.I., Herzog A.G., et al. Reproductive dysfunction in women with epilepsy: recommendations for evaluation and management. J Neurol Neurosurg Psychiatry 73 (2002) 121-125
35. Morrell M.J., Isojarvi J., Taylor A.E., et al. Higher androgens and weight gain with valproate compared with lamotrigine for epilepsy. Epilepsy Res 54 (2003) 189-199
36. Isojarvi J.I. Serum steroid hormones and pituitary function in female epileptic patients during carbamazepine therapy. Epilepsia 31 (1990) 438-445
37. Lossius M.I., Tauboll E., Mowinckel P., Morkrid L., and Gjerstad L. Reversible effects of antiepileptic drugs on reproductive endocrine function in men and women with epilepsy: a prospective randomized double-blind withdrawal study. Epilepsia 48 (2007) 1875-1882
38. Murialdo G., Galimberti C.A., Gianelli M.V., et al. Effects of valproate, phenobarbital, and carbamazepine on sex steroid setup in women with epilepsy. Clin Neuropharmacol 21 (1998) 52-58
39. Quigg M., Kiely J.M., Johnson M.L., Straume M., Bertram E.H., and Evans W.S. Interictal and postictal circadian and ultradian luteinizing hormone secretion in men with temporal lobe epilepsy. Epilepsia 47 (2006) 1452-1459
40. Talbot J.A., Sheldrick R., Caswell H., and Duncan S. Sexual function in men with epilepsy: how important is testosterone?. Neurology 70 (2008) 1346-1352
41. El-Khatib F., Rauchenzauner M., Lechleitner M., et al. Valproate, weight gain and carbohydrate craving: a gender study. Seizure 16 (2007) 226-232
42. Hamed S.A. Leptin and insulin homeostasis in epilepsy: relation to weight adverse conditions. Epilepsy Res 75 (2007) 1-9
43. Hamed SA, Fida NM, Hamed EA. States of serum leptin and insulin in children with epilepsy: risk predictors of weight gain. Eur J Paediatr Neurol; 2008 [EPub ahead of print.]
44. Luef G., Abraham I., Hoppichler F., et al. Increase in postprandial serum insulin levels in epileptic patients with valproic acid therapy. Metabolism 51 (2002) 1274-1278
45. Rauchenzauner M., Haberlandt E., Scholl-Burgi S., et al. Adiponectin and visfatin concentrations in children treated with valproic acid. Epilepsia 49 (2008) 353-357
46. Rauchenzauner M., Haberlandt E., Scholl-Burgi S., et al. Effect of valproic acid treatment on body composition, leptin and the soluble leptin receptor in epileptic children. Epilepsy Res 80 (2008) 142-149
47. Tan H., Orbak Z., Kantarci M., Kocak N., and Karaca L. Valproate-induced insulin resistance in prepubertal girls with epilepsy. J Pediatr Endocrinol Metab 18 (2005) 985-989
48. Hotta K., Funahashi T., Arita Y., et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 20 (2000) 1595-1599
49. Leyva F., Godsland I.F., Ghatei M., et al. Hyperleptinemia as a component of a metabolic syndrome of cardiovascular risk. Arterioscler Thromb Vasc Biol 18 (1998) 928-933
50. Sandhofer A., Laimer M., Ebenbichler C.F., Kaser S., Paulweber B., and Patsch J.R. Soluble leptin receptor and soluble receptor-bound fraction of leptin in the metabolic syndrome. Obes Res 11 (2003) 760-768
51. Tilg H., and Moschen A.R. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 6 (2006) 772-783
52. Halaas J.L., Gajiwala K.S., Maffei M., et al. Weight-reducing effects of the plasma protein encoded by the obese gene. Science 269 (1995) 543-546
53. Lammert A., Kiess W., Bottner A., Glasow A., and Kratzsch J. Soluble leptin receptor represents the main leptin binding activity in human blood. Biochem Biophys Res Commun 283 (2001) 982-988
54. Chandran M., Phillips S.A., Ciaraldi T., and Henry R.R. Adiponectin: more than just another fat cell hormone?. Diabetes Care 26 (2003) 2442-2450
55. Stefan N., Bunt J.C., Salbe A.D., Funahashi T., Matsuzawa Y., and Tataranni P.A. Plasma adiponectin concentrations in children: relationships with obesity and insulinemia. J Clin Endocrinol Metab 87 (2002) 4652-4656
56. Greco R., Latini G., Chiarelli F., Iannetti P., and Verrotti A. Leptin, ghrelin, and adiponectin in epileptic patients treated with valproic acid. Neurology 65 (2005) 1808-1809
57. Kossoff E.H. More fat and fewer seizures: dietary therapies for epilepsy. Lancet Neurol 3 (2004) 415-420
58. Kossoff E.H., and McGrogan J.R. Worldwide use of the ketogenic diet. Epilepsia 46 (2005) 280-289
59. Kossoff E.H., Zupec-Kania B.A., Amark P.E., et al. Optimal clinical management of children receiving the ketogenic diet: recommendations of the International Ketogenic Diet Study Group. Epilepsia 50 (2009) 304-317
60. Kwiterovich Jr. P.O., Vining E.P., Pyzik P., Skolasky Jr. R., and Freeman J.M. Effect of a high-fat ketogenic diet on plasma levels of lipids, lipoproteins, and apolipoproteins in children. JAMA 290 (2003) 912-920
61. Tomson T., Walczak T., Sillanpaa M., and Sander J.W. Sudden unexpected death in epilepsy: a review of incidence and risk factors. Epilepsia 46 Suppl. 11 (2005) 54-61
62. Walczak T.S., Leppik I.E., D'Amelio M., et al. Incidence and risk factors in sudden unexpected death in epilepsy: a prospective cohort study. Neurology 56 (2001) 519-525
63. Nashef L., and Brown S. Epilepsy and sudden death. Lancet 348 (1996) 1324-1325
64. Nashef L., Hindocha N., and Makoff A. Risk factors in sudden death in epilepsy (SUDEP): the quest for mechanisms. Epilepsia 48 (2007) 859-871
65. Nashef L., and Sander J.W. Sudden unexpected deaths in epilepsy: where are we now?. Seizure 5 (1996) 235-238
66. Simona P., Dalager-Pedersen S., Baandrup U., Dam M., and Vesterby-Charles A. Sudden unexpected death in epilepsy: is death by seizures a cardiac disease?. Am J Forens Med Pathol 26 (2005) 99-105
67. Persson H., Kumlien E., Ericson M., and Tomson T. Circadian variation in heart-rate variability in localization-related epilepsy. Epilepsia 48 (2007) 917-922
68. O'Regan M.E., and Brown J.K. Abnormalities in cardiac and respiratory function observed during seizures in childhood. Dev Med Child Neurol 47 (2005) 4-9
69. Tinuper P., Bisulli F., Cerullo A., et al. Ictal bradycardia in partial epileptic seizures: autonomic investigation in three cases and literature review. Brain 124 (2001) 2361-2371
70. Zaatreh M.M., Quint S.R., Tennison M.B., D'Cruz O., and Vaughn B.B. Heart rate variability during interictal epileptiform discharges. Epilepsy Res 54 (2003) 85-90
71. Woodruff B.K., Britton J.W., Tigaran S., et al. Cardiac troponin levels following monitored epileptic seizures. Neurology 60 (2003) 1690-1692
72. Tigaran S., Molgaard H., McClelland R., Dam M., and Jaffe A.S. Evidence of cardiac ischemia during seizures in drug refractory epilepsy patients. Neurology 60 (2003) 492-495
73. Levin E.R., Gardner D.G., and Samson W.K. Natriuretic peptides. N Engl J Med 339 (1998) 321-328
74. McMurray J., Davie A.P., and McClure S.J. Assessment of heart failure with plasma natriuretic peptides. Lancet 351 (1998) 444 author reply 45
75. Yang R.H., Jin H.K., Wyss J.M., Chen Y.F., and Oparil S. Pressor effect of blocking atrial natriuretic peptide in nucleus tractus solitarii. Hypertension 19 (1992) 198-205
76. Takahashi K., Totsune K., Sone M., et al. Human brain natriuretic peptide-like immunoreactivity in human brain. Peptides 13 (1992) 121-123
77. Rauchenzauner M., Haberlandt E., Hogler W., and Luef G. Brain-type natriuretic peptide release and seizure activity during vagal nerve stimulation. Epilepsia 48 (2007) 397-399
78. Souverein P.C., Webb D.J., Petri H., Weil J., Van Staa T.P., and Egberts T. Incidence of fractures among epilepsy patients: a population-based retrospective cohort study in the General Practice Research Database. Epilepsia 46 (2005) 304-310
79. Petty S.J., O'Brien T.J., and Wark J.D. Anti-epileptic medication and bone health. Osteoporos Int 18 (2007) 129-142
80. Pack A.M., and Walczak T.S. Bone health in women with epilepsy: clinical features and potential mechanisms. Int Rev Neurobiol 83 (2008) 305-328
81. Sheth R.D., Binkley N., and Hermann B.P. Gender differences in bone mineral density in epilepsy. Epilepsia 49 (2008) 125-131
82. Sheth R.D., and Hermann B.P. Bone in idiopathic and symptomatic epilepsy. Epilepsy Res 78 (2008) 71-76
83. Farhat G., Yamout B., Mikati M.A., Demirjian S., Sawaya R., and El-Hajj Fuleihan G. Effect of antiepileptic drugs on bone density in ambulatory patients. Neurology 58 (2002) 1348-1353
84. Pack A.M., Morrell M.J., Marcus R., et al. Bone mass and turnover in women with epilepsy on antiepileptic drug monotherapy. Ann Neurol 57 (2005) 252-257
85. Verrotti A., Greco R., Morgese G., and Chiarelli F. Increased bone turnover in epileptic patients treated with carbamazepine. Ann Neurol 47 (2000) 385-388
86. Rauchenzauner M., Schmid A., Heinz-Erian P., et al. Sex- and age-specific reference curves for serum markers of bone turnover in healthy children from 2 months to 18 years. J Clin Endocrinol Metab 92 (2007) 443-449
87. Miller P.D. Bone density and markers of bone turnover in predicting fracture risk and how changes in these measures predict fracture risk reduction. Curr Osteoporos Rep 3 (2005) 103-110
88. Bonnick S.L., and Shulman L. Monitoring osteoporosis therapy: bone mineral density, bone turnover markers, or both?. Am J Med 119 (2006) S25-S31
89. Hannon R.A., and Eastell R. Bone markers and current laboratory assays. Cancer Treat Rev 32 Suppl. 1 (2006) 7-14
90. Cansu A., Serdaroglu A., Camurdan O., Hirfanoglu T., Bideci A., and Gucuyener K. The evaluation of thyroid functions, thyroid antibodies, and thyroid volumes in children with epilepsy during short-term administration of oxcarbazepine and valproate. Epilepsia 47 (2006) 1855-1859
91. Mikati M.A., Tarabay H., Khalil A., Rahi A.C., El Banna D., and Najjar S. Risk factors for development of subclinical hypothyroidism during valproic acid therapy. J Pediatr 151 (2007) 178-181
92. Vainionpaa L.K., Mikkonen K., Rattya J., et al. Thyroid function in girls with epilepsy with carbamazepine, oxcarbazepine, or valproate monotherapy and after withdrawal of medication. Epilepsia 45 (2004) 197-203
93. Verrotti A., Laus M., Scardapane A., Franzoni E., and Chiarelli F. Thyroid hormones in children with epilepsy during long-term administration of carbamazepine and valproate. Eur J Endocrinol 160 (2009) 81